Press Releases
2013
13 May 2013
2013 Annual General Meeting
Access for Participants by Webcast and Conference Call
30 April 2013
GI Dynamics, Inc. Appoints David Maggs, M.D. as Chief Medical Officer
25 April 2013
GI Dynamics, Inc. Reports on Progress of the ENDO Trial
18 March 2013
EndoBarrier® Therapy Named Product of the Year by BioSpectrum Asia
06 March 2013
GI Dynamics Announces Agreement with CMS Medical for Distribution of EndoBarrier® Therapy in Brazil
26 February 2013
GI Dynamics to Present at the Cowen & Co. 33rd Annual Healthcare Conference
26 February 2013
GI Dynamics Announces Commercial Availability of EndoBarrier® Therapy in Israel for the Treatment of Type 2 Diabetes and/or Obesity
19 February 2013
GI Dynamics to Hold Briefing Call and Webcast on
Financial Results for 2012
31 January 2013
Data Show EndoBarrier® Therapy Demonstrates Glycemic Control in People with Type 2 Diabetes Who are Mildly Obese
15 January 2013
GI Dynamics, Inc. Initiates U.S. Pivotal Clinical Trial of EndoBarrier®
09 January 2013
GI Dynamics Announces Resolution of Litigation with Gore
04 January 2013
GI Dynamics Announces Research Collaborations with GlaxoSmithKline and Medtronic
2012
06 November 2012
GI Dynamics to Present at Upcoming Investor Conferences
30 October 2012
GI Dynamics, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of EndoBarrier®
22 October 2012
GI Dynamics to Hold Briefing Call and Webcast on
Financial Results for Third Quarter 2012
22 October 2012
GI Dynamics Announces New Insights into EndoBarrier® Therapy’s Influence on Key Hormones Affecting Satiety and Blood Sugar Control
02 October 2012
Study Shows EndoBarrier® Therapy Offers Improved and Sustained Glycemic Control in People with Type 2 Diabetes Who Are Overweight
24 September 2012
St. Vincent’s Clinic and Macquarie University Hospital in Sydney Incorporate EndoBarrier® Therapy into Type 2 Diabetes and Obesity Treatment Options
23 August 2012
GI Dynamics, Inc. Announces FDA Conditional Approval for Pivotal Clinical Trial of
the EndoBarrier®
23 July 2012
GI Dynamics to Hold Briefing Call and Webcast on
Financial Results for Second Quarter 2012
11 June 2012
Data on GI Dynamics’ EndoBarrier® Therapy Presented at the ADA 72nd Scientific Sessions
01 June 2012
GI Dynamics to Present at the Jefferies 2012 Global Healthcare Conference
31 May 2012
Summary Judgment Ruling on Counterclaims in Gore vs. GI Dynamics Lawsuit
14 May 2012
EndoBarrier® Therapy to be Featured at Digestive Disease Week 2012
01 May 2012
EndoBarrier® Therapy Data Published in Annals of Surgery
27 April 2012
GI Dynamics Announces New Data Demonstrating Feasibility of EndoBarrier® Reimplantation
19 April 2012
GI Dynamics Announces First Cases of EndoBarrier® Therapy in Australia
04 April 2012
GI Dynamics, Inc. Expands Global Commercial Team
07 March 2012
GI Dynamics Designates First EndoBarrier® Center of Excellence in Australia
28 February 2012
GI Dynamics Announces Full-Year 2011 Financial Results
27 February 2012
GI Dynamics to Present at Upcoming Investor Conferences
23 February 2012
GI Dynamics to Hold Briefing Call and Webcast on Financial Results for 2011
09 February 2012
GI Dynamics, Inc. Designates National Obesity Surgery Centre as Center of Excellence in the United Kingdom
05 January 2012
GI Dynamics, Inc. to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
2011
14 December 2011
GI Dynamics, Inc. Expands Availability of the EndoBarrier® Through Two New
Centers of Excellence in Germany
29 November 2011
GI Dynamics to Present at Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference
29 November 2011
GI Dynamics, Inc. Appoints Mark Twyman as Its Chief Commercial Officer
09 November 2011
GI Dynamics to Present at Lazard Capital Markets 8th Annual Healthcare Conference
28 October 2011
Appendix 4C Quarterly Report
21 September 2011
GI Dynamics, Inc. Launches EndoBarrier® in Austria for the Treatment of Type 2 Diabetes and Obesity
16 September 2011
GI Dynamics to Present at UBS Global Life Sciences Conference
15 September 2011
New Data Presented at EASD Reveals EndoBarrier® Effect on GI Hormones Key to Improving Glycemic Control
07 September 2011
GI Dynamics Commences Trading on the ASX Following Successful A$80 Million Offers
23 August 2011
GI Dynamics Welcomes the Addition of Three U.S. and Australian Based Directors to its Board
2010
29 November 2010
GI Dynamics to Present at Upcoming Investment Conferences
01 November 2010
GI Dynamics Shares Insights on Novel Therapies in Type 2 Diabetes at the Cleveland Clinic 2010 Medical Innovation Summit
07 September 2010
GI Dynamics Announces New Data Showing Significant Weight Loss, Cardiovascular and Metabolic Improvements Following 12 Months of EndoBarrier™ Treatment
01 September 2010
GI Dynamics Announces Distribution Agreement with Elemental Healthcare for the
EndoBarrier™ Gastrointestinal Liner
19 August 2010
GI Dynamics Announces Key Executive Appointments in Preparation for European Launch of EndoBarrier™ Gastrointestinal Liner
10 February 2010
GI Dynamics’ EndoBarrier™ Gastrointestinal Liner to be Highlighted at Upcoming Cleveland Clinic Conference
07 January 2010
GI Dynamics Receives Strategic Investment from Medtronic, Inc
2009
11 November 2009
GI Dynamics’ EndoBarrier ™ Gastrointestinal Liner Demonstrates Significant HbA1c Reduction in Obese People Living with Type 2 Diabetes
27 October 2009
GI Dynamics’ EndoBarrier ™ Gastrointestinal Liner Demonstrates Safety and Efficacy in Pre-surgical Weight Loss
26 August 2009
Data from a Clinical Study Evaluating GI Dynamics’ EndoBarrier to be Presented at IFSO
20 April 2009
New Data on GI Dynamics’ EndoBarrier™ Technology Platform to be Presented at Upcoming Medical Meetings
19 February 2009
GI Dynamics Closes an Additional $15 Million in Series C Financing
07 January 2009
GI Dynamics Receives ISO Certification and European CE Mark Approval for the EndoBarrier™ Gastrointestinal Liner System